For personal use only

26 February 2026 **ASX RELEASE**

The Calmer Co raises in an oversubscribed round, scaled back to $1.6 Million, to accelerate U.S. Expansion amid Surging Global Kava Demand

The Calmer Co International Limited (ASX: CCO) is pleased to announce the successful completion of a **$1.6 million placement** to sophisticated investors and professional investors.

The Placement was well supported by new and existing institutional and sophisticated investors and was managed by **Novus Capital Limited** as Lead Manager.

Funds raised will be strategically deployed to accelerate growth across the Company's highest-performing channels, including:

- Inventory build to support large-scale U.S. wholesale supply contracts
- Sales, distribution and marketing expansion across Amazon USA, direct-to-consumer and Australian retail
- General working capital & the cost of the offer

This capital injection positions the Company to further scale its rapidly expanding U.S. wholesale operations and strengthens its leadership position within the high-growth functional relaxation and alcohol alternative categories.

Positioned in a Rapidly Expanding Global Market

The global kava extract market is estimated at US$1.6 billion (2024) and forecast to grow to US$5.6 billion by 2033, representing a CAGR of 14.1%. The U.S. market is experiencing even stronger growth, driven by increasing consumer demand for:

- Functional relaxation products
- Alcohol alternatives
- Natural sleep support solutions

With a 15-year vertically integrated Pacific Island supply chain spanning Fiji, Solomon Islands and PNG, proprietary CO_2 extraction capability, and established retail partnerships including Woolworths Group and Coles Group, The Calmer Co is strategically positioned to capture this structural consumer shift.

For personal use only

The successful placement strengthens the Company's balance sheet, supports inventory expansion to service growing U.S. demand, and positions the business to move toward operational break-even as revenue continues to scale.

The Board thanks investors for their strong support and looks forward to updating shareholders on continued progress across U.S. wholesale, Amazon expansion and retail growth initiatives.

Founder & CEO Zane Yoshida said:

"We are delighted with the strong support shown by sophisticated and existing investors. This capital raise enables us to accelerate U.S. wholesale growth, expand distribution and marketing, and build on our strong revenue momentum. With a scalable supply chain, increasing U.S. market share and structural tailwinds in the alcohol alternative category, we believe The Calmer Co is entering a significant growth phase."

The Placement was conducted at $0.0035 per share through the issue of 457,142,858 fully paid ordinary shares, with participants receiving one (1) free attaching option for every one (1) share subscribed, exercisable at $0.007 with a three-year term (subject to shareholder approval).

Novus Capital Limited will receive a 6% fee, together with 5 million broker shares and 5 million broker options (on the same terms as the attached options, subject to shareholder approval).

The Placement Shares and broker shares will be issued under existing ASX Listing Rule 7.1 and 7.1A issue capacity, while the Options will be issued when shareholder approval under Listing Rule 7.1 is obtained.

The Share component of the Placement is expected to settle on 17 March 2026, while issue of the options will occur subject to receipt of the required shareholder approval under Listing Rule 7.1.

The Company proposes to call a general meeting shortly to seek approval for issue of the options.

This announcement has been approved for release by the Board of The Calmer Co. International Limited

For further information

Investor & Media Relations
Zane Yoshida
investors@thecalmerco.com

THE CALMER CO.

For personal use only

About The Calmer Co.

The Calmer Co. International Limited (ASX:CCO) is a fast-growing beverage business leveraging a global opportunity in kava and other natural products that replace alcohol and support relaxation and sleep.

Our products are delivered to consumers globally through e-commerce channels and blue-chip retail distribution partners, supported by a reliable farm to shelf supply chain.

The product range includes drinking powders, natural and flavoured kava shots, concentrates and capsules, sold under the brands Fiji Kava®, Taki Mai® and Danodan Hempworks in markets including USA, Australia, New Zealand, China and the Pacific Islands.

Forward looking statements

This ASX release includes certain forward-looking statements that are based on information and assumptions known to date and are subject to various risks and uncertainties. Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of the Company. These factors may cause actual results to differ materially from those expressed in the statements contained in this announcement.